Xenoport, Inc.

Affymax Technologies, N.v.

Arixa Pharmaceuticals, Inc.

Affymax, Inc.

Rubedo Life Sciences, Inc.

Other

University of California

Glaxo Group Limited

Glaxo Wellcome Inc.

Arbor Pharmaceuticals, LLC

Xero Port, Inc.

Mark A Gallop

Kenneth C Cundy

Fenmei Yao

Jia-Ning Xiang

Cindy X Zhou

Ronald W Barrett

Ge Peng

Xuedong Dai

Thu Phan

William J Dower

Feng Xu

Laxminarayan Bhat

Maria J Ludwikow

Randall A Scheuerman

Bernd Jandeleit

Noa Zerangue

Stephen P Raillard

Suresh Kumar Manthati

Jianhua Li

Mark Quang Nguyen

Yunxiao Li

Thomas F Woiwode

Eric M Gordon

Peter Virsik

Seema Rani Bhat

Nelson L Jumbe

Usha Dilip

Michael C Needels

Fayang Gregory Qiu

Steven E Cwirla

John Freund

Ian R Ollman

Matthew Alexander James Duncton

Derek Maclean

Zhi-Jie Ni

Wolf-Nicolas Fischer

Archana Gangakhedkar

Martin A Murphy

Nikhil Shah

Marco Quarta

Peter G Schultz

Christopher P Holmes

David Juergen Wustrow

David A Campbell

Ian R Ollmann

Vivek Sasikumar

William L Fitch

Qingzhi Gao

William Fitch

Tania Chernov-Rogan

Thomas W Woiwode

Julian Klein

Vivek Susikumar

Christopher Holmes

Gus Bergnes

Paul Keitz

Peter A Virsik

Maria Ludwikow

Fayang G Qiu

Provided herein are novel sugar derivatives which are intermediates for preparing senolytic agents that selectively kill senescent cells associated with numerous pathologies and diseases, including age-related pathologies and diseases.

Sugar derivatives and uses thereof to prepare novel senolytic agents

Provided herein are senolytic agents for selectively killing senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies and diseases. As disclosed herein, senescent cell-associated diseases and disorders may be treated or prevented by administering at least one senolytic agent or pharmaceutical compositions thereof. The senescent cell-associated diseases or disorders treated or prevented by the methods described herein include, but are not limited to, cardiovascular diseases or disorders, cardiovascular diseases and disorders associated with arteriosclerosis, such as atherosclerosis, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), osteoarthritis, inflammatory diseases or disorders, autoimmune diseases or disorders, pulmonary diseases or disorders, neurological diseases or disorders, dermatological diseases or disorders, chemotherapeutic side effects, radiotherapy side effects, metastasis and metabolic diseases.

Senolytic compositions and uses thereof

&#x3b2;-Lactamase inhibiting compounds, therapeutic methods of using the &#x3b2;-lactamase inhibiting compounds, particularly in combination with &#x3b2;-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The &#x3b2;-lactamase inhibiting compounds are suitable for oral administration.

Beta-lactamase inhibitors and uses thereof

The disclosures herein relate generally to acyloxyalkyl carbamate prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, pharmaceutical compositions thereof, methods of making prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, methods of using prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing common diseases and/or disorders such as spasticity and/or acid reflux disease. The disclosures herein also relate to acyloxyalkyl carbamate prodrugs of (&#xb1;)-4-amino-3-(4-chlorophenyl)butanoic acid and analogs thereof which are suitable for oral administration and to sustained release oral dosage forms thereof.

Acyloxyalkyl carbamate prodrugs, methods of synthesis and use

Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof

The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

Prodrugs of gaba analogs, compositions and uses thereof

Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, pharmaceutical compositions thereof, methods of making prodrugs of trans-4-(aminomethyl)-cyclohexane-carboxylic acid, and methods of using prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof to treat or prevent various diseases or disorders are disclosed. Acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof suitable for oral and topical administration and for administration using sustained release dosage forms are also disclosed.

Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use

Methods of using prodrugs of pregabalin

Gamma-amino-butyric acid derivatives that are GABAreceptor ligands, pharmaceutical compositions comprising such derivatives, and methods of using such derivatives and pharmaceutical compositions thereof for treating diseases are disclosed.

[object Object]

A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.

Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use

Pantoic acid ester neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use

Growing community of inventors

Los Altos, CA, United States of America

Mark A Gallop